Internal Medicine Alert
RSSArticles
-
ECG Review: What are the Clinical Implications of this Rhythm?
This tracing was obtained from a 69-year-old woman with a long-term history of palpitations. Her symptoms had been increasing over recent weeks, in association with “chest tightness” and dizziness. Her prior medical history was benign, and she was hemodynamically stable at the time this tracing was recorded. How would you interpret this rhythm strip? What are the clinical implications of this rhythm?
-
Clinical Briefs
A closer look at non-alcoholic fatty liver disease, lifting the ban on total dietary fat, and the risks of digoxin use in AF patients.
-
Cholic Acid Capsules (Cholbam ®)
The cholic acid capsule is the first FDA-approved treatment for rare bile acid synthesis disorders.
-
Inferior Vena Cava Filters and Recurrent Pulmonary Embolism
Placement of retrievable inferior vena cava filters in individuals with concurrent deep vein thrombosis does not reduce the risk of recurrent pulmonary embolism.
-
Long-term Weight Loss Rivals Medications and Ablation for AF Rhythm Control
The authors conclude long-term sustained weight loss was possible and was associated with a significant reduction in atrial fibrillation burden.
-
Provocative Cardiovascular Testing for Everyone with Chest Pain?
ABSTRACT & COMMENTARY: Pain or not, it's hard to take money out of the medical equation.
-
Clinical Brief
Briefs -
Dulaglutide Injection (Trulicity™)
The FDA has approved a third long-acting, once-weekly, glucagon-like peptide (GLP-1) receptor agonist for the treatment of type 2 diabetes mellitus, joining exenetide ER and albiglutide. Dulaglutide is made up of two identical human-based GLP-1 analogs linked to a modified human IgG4 Fc fragment. This makes the molecule resistant to degradation by DPP-4, slows absorption, reduces renal clearance, and extends the elimination half-life to approximately 5 days. Dulaglutide is marketed by Eli Lilly as Trulicity.
-
Angiotensin Receptor Blockers for Hypertension
Angiotensin receptor blockers (ARBs) are often used as first-line therapy for the treatment of systemic hypertension because of their perceived efficacy and relatively low incidence of adverse effects.
-
Colchicine for Recurrent Pericarditis
Although colchicine has been shown to be effective for the treatment of acute pericarditis and first recurrences, little information exists about its use in patients with multiple recurrences.